1. Scrip
  2. >>New Products

CTI Bites Off Big Chunk Of Myelofibrosis Market With Vonjo Approval

 
• By Alaric DeArment

The accelerated approval for the JAK2/IRAK1 inhibitor, CTI’s first commercial product, carves out an underserved market accounting for about one-third of the US myelofibrosis population.

FDA Approved
CTI won its first FDA approval, with the agency giving its nod to the myelofibrosis drug Vonjo • Source: Shutterstock

CTI BioPharma Corp. will tap a huge percentage of the myelofibrosis market poorly served by existing therapies with the approval of its JAK2/IRAK1 inhibitor, Vonjo (pacritinib), as it prepares to make the drug available in less than two weeks.

The US Food and Drug Administration gave the drug accelerated approval on 28 February for patients with intermediate- or high-risk primary or secondary myelofibrosis with thrombocytopenia with a platelet count of less than 50

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip